| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 2,220 | 11,490 | 9,020 | 26,520 | 53,590 |
| Sales Growth | -80.68% | +27.38% | -65.99% | -50.51% | +11.51% |
| Net Income | -311,900 | -297,390 | -247,750 | -290,170 | -80,550 |
| Net Income Growth | -4.88% | -20.04% | +14.62% | -260.24% | -68.97% |
Reata Pharma
(RETA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively.
Fiscal Year End Date: 12/31